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A B S T R A C T
In randomized clinical trials (RCTs) with teriparatide, the number of patients with incident hip fractures was
small and insufficiently powered to show statistically significant differences between groups. We, therefore,
conducted a systematic review and meta-analysis of the efficacy of teriparatide in the reduction of hip and upper
limb fractures in women and men with osteoporosis. A comprehensive search of databases until 22 November
2017 was conducted for RCTs of at least 6-month duration that reported non-spine fractures (hip, humerus,
forearm, wrist), either as an efficacy or safety endpoint. Only RCTs that included patients with the approved
treatment indications and dose for use of teriparatide were included; trials with off-label use of teriparatide were
excluded. Two independent reviewers performed study selection and data extraction. Statistical procedures
included Peto's method and Mantel-Haenszel with empirical correction, as most of the RCTs reported zero events
in at least one of the treatment arms. Study results are expressed as odds ratios (OR) with 95% confidence
intervals (CI). Publication bias and heterogeneity were evaluated with standard statistical tests. Twenty-three
RCTs were included, 19 with an active-controlled arm (representing 64.9% of the patients included in the control
group) and 11 double-blind, representing data on 8644 subjects, 3893 of them treated with teriparatide. Mean
age (SD) was 67.0 (4.5) years, median treatment duration 18months (range: 6 to 24months). A total of 34
incident hip, 31 humerus, 31 forearm, and 62 wrist fractures were included. Meta-analysis results showed an OR
(95% CI) for hip fractures of 0.44 (0.22–0.87; p=0.019) in patients treated with teriparatide compared with
controls. The effects on the risk of humerus [1.02 (0.50–2.08)], forearm [0.53 (0.26–1.08)] and wrist fractures
[1.21 (0.72–2.04)] were not statistically significant (p > 0.05). This meta-analysis provides evidence of efficacy
of teriparatide in reducing hip fractures by 56% in patients with osteoporosis.
1. Introduction
Typically, osteoporosis randomized control trials have primary
endpoints of vertebral fractures, since this is the most frequent fracture
experienced in postmenopausal women. Hip fractures are seldom pri-
mary endpoints due to their infrequent nature in elderly patients, who
are not often recruited to registration clinical trials. The main objective
of the pivotal, phase 3 teriparatide studies in patients with
postmenopausal osteoporosis was to investigate vertebral anti-fracture
efficacy, while phase 4 trials were primarily aimed to investigate the
effects on surrogate markers of bone strength and structure in a limited
number of patients. Even though many of these studies included sub-
jects at high risk for having osteoporotic fractures, the number of in-
cident hip fractures was relatively small and insufficient to show sta-
tistically significant differences between groups. For example, the
teriparatide clinical trial with the most hip fractures published to date
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reported only 9 such fractures [1], while the pivotal, phase 3 trial of
teriparatide in postmenopausal osteoporosis reported only 5 hip fragi-
lity fractures between the placebo and the teriparatide 20 μg treatment
arms [2]. In the largest randomized clinical trial that included a ter-
iparatide treatment arm, only 2 hip fractures were collected in the total
clinical trial cohort [3].
However, results from non-controlled, observational studies with
larger patient cohorts, suggest that teriparatide may reduce the risk of
hip fractures [4–7]. Understanding the effects of treatment of ter-
iparatide on hip fractures is important given the clinical impact and
health economic importance of this type of fractures, and the lack of
data from individual randomized clinical trials adequately powered to
evaluate the efficacy of this drug on hip fractures.
The primary aim of this systematic review and meta-analysis was to
evaluate the efficacy of teriparatide in the reduction of hip fractures in
women and men with osteoporosis. The secondary objective was the
investigation of the effects of teriparatide on upper limb fractures (i.e.
humerus, forearm and wrist), in order to evaluate the fracture results in
non-weight bearing bones.
2. Material and methods
2.1. Literature search strategy
We designed this study according to the Preferred Reporting Items
for Systematic Reviews and Meta-Analysis Guidelines [8]. The protocol
was registered in the International Prospective Register of Systematic
Reviews, PROSPERO (registration number: CRD42018085635).
A comprehensive search strategy aimed to identify RCTs that re-
ported non-spine fractures either as an efficacy or safety endpoint,
published in English, French or Spanish until 22 November 2017.
Literature searches on MEDLINE (OVID interface, 1948 onwards) and
EMBASE (OVID interface, 1974 onwards) were performed. Keywords
were identified with medical subject headings (MeSH) and text words
related to “teriparatide” and “parathyroid hormone (1-34)”. Additional
sources included searches in clinical trial repositories (clinicaltrials.gov
and EUDRAC), and contact with main authors and manufactures that
owned study reports of clinical trials on teriparatide that missed some
fracture site details in the peer-reviewed publications.
2.2. Selection criteria
The main outcome of interest was the incidence of fragility, low
trauma hip fractures following teriparatide treatment. Eligible studies
met the following inclusion criteria: (1) RCTs with study participants
treated according to the approved indications for the use of teriparatide
in the USA, Europe and Japan (i.e.; postmenopausal and male osteo-
porosis, glucocorticoid-induced osteoporosis); (2) minimum of 6-month
treatment exposure; (3) a maximum treatment duration as approved
(i.e.; 24months), at the approved dose (20 μg/day subcutaneously) [9],
and (4) controlled with placebo or other active anti-osteoporosis drug,
either commercially available, or under clinical development. Narrative
reviews, observational studies, comments, opinion pieces, methodolo-
gical reports, editorials, and letters were excluded. Reviews were
screened to check for potential additional studies that were not pub-
lished as standalone papers.
Following the screening of titles and abstracts, duplicates were re-
moved. If multiple reports were available from the same study, fracture
data from the most recent report were included. Two authors (ADP and
FM) independently analyzed the titles and abstracts and then performed
the study selection and evaluation of quality and data extraction of the
full papers. Discrepancies were resolved by consensus between the re-
viewer authors.
2.3. Data extraction and management
Data extracted from each study included participants, interventions,
description of the comparators, and outcomes with the following spe-
cific items: first author, reference, year of publication, control group,
participants' characteristics [gender, age], study design, clinical devel-
opment phase, incident selected non-vertebral fractures, type of frac-
ture endpoint (efficacy or safety), and duration of treatment. In the case
of forearm and wrist fractures, the fracture site term was kept as re-
ported in the original publication; fractures reported at the “radius”
were included in the forearm fractures analysis, while fractures re-
ported at “carpal bones” were included in the wrist fractures analysis.
The lack of detailed results of other individual non-vertebral fracture
sites in most of the publications precluded a pooled analysis of all non-
vertebral fractures.
For consistency with the primary objective, we focused the analysis
on low trauma, fragility upper limb fractures when that information
was explicitly disclosed in the publications.
2.4. Quality assessment
The scale recommended by the Cochrane Collaboration [10] was
used to assess the methodological quality of identified studies as well as
the risk of bias of the individual included. The major criteria of the
checklist were randomization, double blind (both patients and re-
searcher/assessor), comparability of treatment groups, available follow-
up information and equal treatment used for treatment groups. Each
criterion might be answered in three ways: yes (adequate information),
no (inadequate information), or unclear information.
2.5. Data synthesis and statistical analysis
As it was expected that many studies would report zero fractures in
at least one of the treatment arms, two procedures were applied to
estimate the risk of fracture: odds ratio (OR) by the Peto's method and
Mantel-Haenszel with empirical correction, with 95% confidence in-
tervals (CI) [11]. Differences were considered statistically significant
when p-value was<0.05. If there were more than two comparators in
the same trial, the results of the comparators were pooled initially, and
separated in sensitivity analysis (placebo and active comparators). A
random effects model was not considered a priori, as heterogeneity is
very uncommon when the data are sparse. Statistical heterogeneity was
tested using the Q test (significance level: 0.1) and I2 statistic (0% to
40%: might not be important; 30% to 60%: may represent moderate
heterogeneity; 50% to 90%: may represent substantial heterogeneity;
75% to 100%: considerable heterogeneity). Meta-regression procedures
were applied to ascertain whether mean age and duration of trial had
an influence on the risk of fracture. An assessment for publication bias
was performed with a visual inspection of funnel plot asymmetry and
also by Egger weighted regression tests [12,13].
A pre-planned sensitivity analysis was performed by removing the
two clinical trials that did not report the hip fracture details in the peer-
reviewed publications, but in clinical study reports filed by the studies
sponsor [14,15].
Analyses were performed using the Stata 15 statistical package
(College Station, TX, USA).
2.6. Subgroup analysis
To address heterogeneity among study populations, pre-specified
subgroup analyses were performed as follows: type of comparator
(placebo or active-treatment osteoporosis drug), type of randomization
(double-blind or open-label), patient characteristics (age and gender)
and follow-up period duration.
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3. Results
3.1. Summary of searches and study selection process
A total of 609 citations were identified through searches plus 4 on-
file clinical trial reports, of which 404 records remained after removal
of duplicates. After screening via titles and abstracts, 372 articles and
study reports remained for further evaluation. Following further eva-
luation, 310 more articles were excluded for the following reasons: not
a RCT, off-label use of teriparatide, non-approved doses, testing of
combination therapies with other anti-osteoporosis drugs, or they were
non-human studies. In many instances, more than one exclusion criteria
applied. Sixty-two records remained for full-text assessment, 39 of them
were further excluded because the index drug was weekly teriparatide,
no fracture results were included, or they were published in languages
other than English, French or Spanish. Therefore, a total of 23 clinical
trials published between 2001 and 2017 were included in the current
meta-analysis (Fig. 1).
Detailed information of the included studies is summarized in
Table 1. Twenty-three RCTs were included, representing data on 8644
subjects, 3893 of them treated with teriparatide. Eight trials were
double-blind during the full study follow-up [2,14,16–21], 12 open-
label [3,22–33], and 3 trials had a mixed design with an initial double-
blind phase (6 to 12months duration) followed by an open-label phase
for up to 18 to 24months [1,15,34] (Table 1). There were 4 placebo-
controlled trials [2,15,16,18], 17 active-controlled trials
[1,14,17,19–34], one three-arm study [3], and one multiple-arm study
[31], where teriparatide was used open-label as an active comparator in
randomized clinical trials of abaloparatide and romosozumab respec-
tively. The active-comparators were risedronate [1,19–21,24,28],
alendronate [14,26,31], zoledronic acid [27,34], calcitonin [22,23],
strontium ranelate [25], denosumab [29,30,32], abaloparatide [3] and
romosozumab [31,33]. In the control group, 1667 (35.1%) patients
received placebo and 3084 (64.9%) patients an active comparator
(Table 2). Seventeen studies were of women with postmenopausal os-
teoporosis, 3 studies included exclusively men [16,20,28], and 3 studies
included a mixed population of men and women [1,14,15] (Table 1). Of
all subjects, there were 545 men (6.3% of the total subjects) (Table 1).
Two studies were of patients with glucocorticoid-induced osteoporosis
[14,28] for a total of 520 patients (6.0% of the total included subjects).
Overall, subjects' mean age (SD) was 67.0 (4.5) years, and the median
teriparatide treatment duration was 18months (range: 6 to 24months).
3.2. Risk of bias assessment
All included studies had a low risk of bias according to randomi-
zation, allocation concealment, and comparability of intervention
groups at the beginning of the trial and equal treatment of intervention
groups (Supplemental Table 1). No evidence of publication bias was
detected using funnel plot or Egger's test (intercept= 0.94; 95% CI:
−3.00 to 1.12, p=0.315).
3.3. Pooled estimate of the effect of teriparatide on hip and upper limb bones
fractures
A total of 34 incident hip, 31 humerus, 31 forearm, and 62 wrist
fractures were reported (Table 2). In 14 studies, representing 1651
patients, no hip fractures were reported [16–18,20,22–27,29–32,34]
(Table 1). Meta-analysis results showed an OR (95% CI) for hip frac-
tures of 0.44 (0.22–0.87; p= 0.019) in patients treated with teripara-
tide compared with controls (Fig. 2). The effects on the risk of humerus
[OR (95%CI): 1.02 (0.50–2.08)], forearm [OR (95%CI): 0.53
Fig. 1. Study selection flow diagram (preferred reporting items for systematic reviews and meta-analysis).
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(026–1.08)] and wrist fractures [OR (95%CI): 1.21 (0.72–2.04)] were
not statistically significant (p > 0.05) (Fig. 3a–c). The effect on the risk
of combined upper limb fractures was non-significant [OR (95%CI):
0.94 (0.65–1.35)] (p > 0.05) or by type of comparator (Supplemental
Fig. S3).
In a subgroup analysis based on the type of comparator (placebo or
active), a significant risk reduction for hip fractures was observed in the
placebo stratum [OR (95%CI): 0.20 (0.05–0.81); p= 0.024; hetero-
geneity Chi-squared: 0.73, I2=0.0% (p=0.694)], but not in the ac-
tive-comparator stratum [OR (95%CI): 0.54 (0.25–1.17); p= 0.118;
heterogeneity Chi-squared: 5.71, I2=12.5% (p= 0.335)]
(Supplemental Fig. S1). The analysis of the hip fracture results by study
blinding (double-blind vs open-label) showed a borderline non-sig-
nificant reduction in both strata: the ORs (95% CI) were 0.50
[(0.24–1.03); p= 0.059] for the double-blind, and 0.44 [(0.22–0.87);
p= 0.089] for the open-label strata (Supplemental Fig. S2). The non-
statistical differences for the individual upper limb fracture sites re-
mained similar in these subgroups analyses (data not included), with
the exception of a statistical significant increased OR for wrist fractures
in the analysis of teriparatide versus active comparators [OR (95%CI):
1.93 (1.02–3.65); p= 0.045].
There was no indication for a relationship between fracture risk
reduction and patients' age or the clinical trial duration. Analysis by
gender was not feasible given the low number of hip fractures in male
subjects (n=1).
After removing the 2 hip fractures that were not described in the in
the peer-reviewed papers [14,15], but which were included in the
clinical study reports, the hip fracture risk remained statistically
reduced [OR (95%CI): 0.49 (0.24–0.98); p= 0.045; heterogeneity Chi-
squared: 5.92, I2=0.0% (p=0.432)].
4. Discussion
Our meta-analysis based on 8644 subjects enrolled in 23 rando-
mized, controlled clinical trials of> 6-month duration, shows that
teriparatide 20 μg per day reduces the risk of hip fractures by 56% after
a median treatment duration of 18months. The analysis of the upper
limb bones fractures showed neutral effects of teriparatide on the risk of
fractures in these non-weight bearing bones.
These results complement previous meta-analysis that has shown
the statistically significant efficacy of teriparatide in reducing the risk of
vertebral and non-vertebral fractures in postmenopausal women with
osteoporosis [35–39]. Our findings of the hip fracture efficacy also
confirms previous results by Murad et al. [38] who reported in a net-
work meta-analysis, combining direct and indirect estimates, that ter-
iparatide had the highest probability (42%) of being ranked as most
effective and had the highest reduction in the risk of hip fracture (OR,
0.42). However, the review by Murad et al. [38] included several stu-
dies with non-approved teriparatide doses for the treatment of osteo-
porosis (40 and 100 μg/day), and only 4 of the 23 RCTs that we have
included in the present systematic review were analyzed.
The findings of this meta-analysis are consistent with several other
lines of evidence suggesting that teriparatide is likely to reduce the risk
of hip fractures, including that teriparatide increases cancellous bone
volume, improves bone architecture, and increases cortical thickness
associated with increased cortical remodeling at the hip [4,40], which
Table 1
Characteristics of the included RCTs of teriparatide and hip and upper limb fractures included in the meta-analysis.
Study alias Patients (n) Study
population









Neer 2001 [2] 1085 PMW 69.0 0 Placebo DB VFx Efficacy 21 3
Hadji 2012 [19] 710 PMW 71.0 0 Risedronate DB Back pain Efficacy 18 3b
Malouf 2017 [1] 216 PMW and men 76.8 22.8 Risedronate DB+OL BMD Safety 18 4
Glüer 2013 [28] 92 GIO 56.3 100 Risedronate OL BMD Safety 18 3b
Kendler 2018 [21] 1360 PMW 72.1 0 Risedronate DB VFx Efficacy 24 4
Miller 2016 [3] 2463 PMW 68.8 0 Placebo/Abaloparatide OL VFx Efficacy 18 3
Leder 2014
[29,30]
64 PMW 65.9 0 Denosumab OL BMD Safety 24 4
Cosman 2011 [27] 275 PMW 65.0 0 Zoledronic Acid OL BMD Safety 12 4
Dempster 2016
[34]
69 PMW 64.5 0 Zoledronic Acid DB+OL Biopsy Safety 24 4
Kung 2006 [22] 104 PMW 70.6 0 Calcitonin OL BMD Safety 6 4
Recker 2009 [25] 79 PMW 64.6 0 Strontium OL Biopsy Safety 6 4
Walker 2013 [20] 19 Men 52.8 100 Risedronate DB BMD Safety 18 4
Dempster 2016
[32]
69 PMW 63.4 0 Denosumab OL Biopsy Safety 6 4
Saag 2007 [14] 428 PMW and men
GIO
56.7 19.4 Alendronate DB BMD Safety 18 3
McClung 2005
[17]
203 PMW 66.0 0 Alendronate DB BMD Safety 18 3
Orwoll 2003 [16] 298 Men 59.0 100 Placebo DB BMD Safety 11 3
Miyauchi 2010
[15]
203 PMW and men 69.6 7 Placebo DB+OL BMD Safety 24 3
McClung 2014
[31]
206 PMW 66.7 0 Placebo/Alendronate/
Romosozumaba
OL BMD Safety 12 2
Panico 2011 [26] 81 PMW 62.5 0 Alendronate OL BMD Safety 18 4
Miyauchi 2008
[18]
77 PMW 70.7 0 Placebo DB BMD Safety 6 2
Anastasilakis 2008
[24]
44 PMW 65.1 0 Risedronate OL BMD Safety 12 4
Hwang 2006 [23] 63 PMW 67.5 0 Calcitonin OL BMD Safety 6 4
Langdahl 2017
[33]
436 PMW 71.5 0 Romosozumab OL BMD Safety 12 3
Abbreviations: BMD: Bone Mineral Density (areal or volumetric); DB: Double Blind; GIO: Glucocorticoid-induced osteoporosis; OL: Open Label; PMW:
Postmenopausal women; VFx: Vertebral Fractures.
a Only the romosozumab 210mg once monthly arm was included to match the phase 3 trials selected dose.
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results in improved biomechanical properties [41]. Additionally, ter-
iparatide 20 μg/day increased femoral neck and total hip BMD during
ongoing treatment through 24months [42]. Also, an analysis of the
Direct Assessment of Nonvertebral Fractures in Community Experience
(DANCE) observational study of 4085 men and women treated with
teriparatide for 24months, showed the rate of hip fractures decreased
as treatment duration increased [4]. Finally, the real-world experience
of teriparatide in reducing the risk of fractures showed hip fractures
Table 2
Sample size and number of hip, humerus, forearm and wrist fractures for each study included in the meta-analysis.


















Neer 2001 [2] Placebo 541 1 2 NR 2 544 4 2 NR 7
Hadji 2012 [19] Risedronate 360 5 4 0a 4 350 2 5 4a 2
Malouf 2017 [1] Risedronate 106 2 1 1a 0 110 7 1 0a 0
Glüer 2013 [28] Risedronate 45 0 0 0 0 47 1 0 1 0
Kendler 2018 [21] Risedronate 680 2 4 6 2 680 5 2 10 1
Miller 2016 [3] Placebo/
Abaloparatide
818 0 2 0 17 821/824 2/0 3/1 4/1 15/7
Leder 2014
[29,30]
Denosumab 31 0 NR NR NR 33 0 NR NR NR
Cosman 2011 [27] Zoledronic Acid 138 0 0 0 1 137 0 1 0 2
Dempster 2016
[34]
Zoledronic Acid 34 0 NR NR NR 35 0 NR NR NR
Kung 2006 [22] Calcitonin 47 0 0 0 0 57 0 0 0 0
Recker 2009 [25] Strontium 39 0 0 0 0 40 0 0 0 0
Walker 2013 [20] Risedronate 9 0 0 0 0 10 0 0 0 0
Dempster 2016
[32]
Denosumab 33 0 NR NR NR 36 0 NR NR NR
Saag 2007 [14]a Alendronate 214 0 0 1 0 214 1 0 0 0
McClung 2005
[17]
Alendronate 102 0 0 0 1 101 0 0 0 0
Orwoll 2003 [16] Placebo 151 0 0 1 0 147 0 0 0 0
Miyauchi 2010
[15]a





54 0 0 0 0 50/51/
51
0/0/0 0/0/0 0/0/0 0/0/1
Panico 2011 [26] Alendronate 42 0 0 0 0 39 0 0 0 0
Miyauchi 2008
[18]
Placebo 39 0 0 0 0 38 0 0 0 0
Anastasilakis 2008
[24]
Risedronate 22 0 0 0 0 22 0 0 0 0
Hwang 2006 [23] Calcitonin 34 0 0 0 0 29 0 0 0 0
Langdahl 2017
[33]
Romosozumab 218 0 1 1 0 218 1 0 0 0
Total 3893 10 15 10 27 4751 24 16 21 35
COMP(S): Comparator(s); NR: Not Reported; TPTD: Teriparatide.
a Fracture Data: Lilly Data on File.
Fig. 2. Forest plot of hip fracture outcomes.
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decreased as adherence and persistence to teriparatide treatment in-
creased [6].
Of note, the hip fracture efficacy with teriparatide was detected
after a relatively short median treatment duration of 18months, with a
maximum treatment duration in the included studies of 24months. The
pivotal trial for teriparatide [2] was discontinued early because of
safety concerns raised by preclinical findings of increased risk of os-
teosarcoma in rats [43], precluding the completion of the planned 3-
year treatment duration, and the likely accumulation of higher numbers
of hip fractures. The approved maximum duration of teriparatide
treatment of 24months is shorter than for other osteoporosis treat-
ments, which limits the ability to show hip fracture efficacy in
Fig. 3. Forest plots of upper limb fracture outcomes: (a) humerus, (b) forearm, (c) wrist.
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individual clinical trials. Therefore, the demonstration of hip anti-
fracture efficacy in this meta-analysis is important and clinically re-
levant information since reduction in hip fracture risk is one of the
major efficacy outcomes for osteoporosis treatments because of their
associated morbidity, mortality and socioeconomic burden.
Previous studies have shown that teriparatide induces a transient,
early decrease in bone density at the proximal femur in patients pre-
treated with antiresorptive drugs [33,44,45]. Imaging and histological
studies show increased cortical porosity in patients initiating teripara-
tide therapy, probably reflecting increased cortical bone remodeling
[46,47]. Although none of these studies show increased hip fracture
risk, this finding has been a concern for some clinicians [48]. Our study
helps to clarify that teriparatide was not associated with any long-term
safety issues regarding cortical-rich fracture sites, rather the opposite.
However, the meta-analytical approach did not permit an evaluation of
the time course of this reduction. Similarly, cortical bone mineral
density loss at the distal radius [2,49] has also been a concern. How-
ever, our meta-analysis showed a neutral effect on forearm and wrist
fractures overall.
This meta-analysis has some limitations. The total number of hip
fractures (n=34) is small, however, the number of fractures we col-
lected in the teriparatide intervention arm (n= 10) vs. the comparator
arms (n=24) was similar to that in the alendronate pivotal FIT-I trial
(n= 11 in alendronate and n=22 hip fractures in placebo) [50], but
lower than in other pivotal studies including the HORIZON trial for
zoledronate (n=140 hip fractures) [51], the FREEDOM trial for de-
nosumab (n=70 hip fractures) [52], and the HIP trial for risedronate
(n=101 hip fractures) [53]. These trials were, however, of longer
treatment duration (2.9 years in FIT-I, and 3 years in the other studies),
and were compared with placebo. In the present meta-analysis, how-
ever, 19 out of the 23 analyzed clinical trials had one or two active
comparator arms with several drugs that have already shown anti-
fracture efficacy at the hip, representing 64.9% of the patients included
in the control group, that might have decreased the effect size of ter-
iparatide in the results. Another limitation is that we pool clinical trials
of postmenopausal women, men, and patients on glucocorticoid
therapy where the risk for hip fractures may be different. Finally, we
were unable to do a systematic review of other individual non-vertebral
fracture sites given the incomplete reporting in most of the studies. In
fact, in only 4 of the 23 included clinical trials, were non-vertebral
fractures analyzed as an efficacy endpoint, while in most of them these
fractures were reported as adverse events in the safety section.
The strength of this review is its comprehensive nature, including
randomized, controlled trials with active comparators or placebo at the
approved teriparatide dose in the approved indications for its use. This
approach reduced the potential risk of recall and selection bias. We
assessed four fracture outcomes: hip, humerus, forearm and wrist. This
is the first systematic analysis of the efficacy of teriparatide at in-
dividual fracture sites of the upper limb.
5. Conclusions
Our systematic review and individual-level meta-analyses of 23
randomized clinical trials comparing teriparatide to placebo or other
anti-osteoporosis drugs in a total of 8644 subjects with osteoporosis in
the approved indications for its clinical use, indicate that there is a
significant reduction of hip fracture and a neutral effect on the pooled
upper limb fractures reported. Collectively, these results support con-
sideration of teriparatide for the treatment of osteoporosis as a first-line
therapy in patients at high risk for osteoporotic fractures, although they
should be interpreted in the context of the relatively small number of
reported hip fractures.
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.bone.2018.09.020.
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